Rastrum bioprinter

Australian bioprinting startup Inventia Life Science and the multinational MSD Pharmaceuticals Private Limited, a wholly-owned subsidiary of Merck Sharp and Dohme known as Merck in the U.S. and Canada, will…

Australian bioprinting startup Inventia Life Science is expanding its local footprint with support from the New South Wales (NSW) government. The Alexandria-based biotech company, a global leader in 3D cell…

Bioprinting machine manufacturer Inventia Life Science has opened its first U.S. office and facility at Delaware NGO The Innovation Space. The Sydney, Australia-based startup will benefit from the rich life…

After announcing a Series B round last January, Sydney-headquartered biotech startup Inventia received an additional AU$4.4 million ($3.2 million) from Australian pension fund giant HESTA. This latest investment brings Inventia’s…

In a Series B round led by Australia’s largest venture capital (VC) firm, Blackbird Ventures, Sydney-headquartered biotech startup Inventia raised $25 million (A$35 million). The company also landed in the…

At a time when experts predict cancer will remain a massive health problem, advances in technology can make a big difference. Earlier this year, the World Health Organization (WHO) announced…

No disease has ever been as overwhelming as cancer. Not only does it kill close to 10 million people every year, but even though we still fail to understand how…

In 2018, Sydney-based startup Inventia Life Science and researchers at the University of New South Wales (UNSW) built Rastrum, a new bioprinter which uses inkjet technology to print human cells…